JOP20170148A1 - مثبطات Wnt لعلاج التليف - Google Patents

مثبطات Wnt لعلاج التليف

Info

Publication number
JOP20170148A1
JOP20170148A1 JOJO/P/2017/0148A JOP20170148A JOP20170148A1 JO P20170148 A1 JOP20170148 A1 JO P20170148A1 JO P20170148 A JOP20170148 A JO P20170148A JO P20170148 A1 JOP20170148 A1 JO P20170148A1
Authority
JO
Jordan
Prior art keywords
fibrosis
treatment
wnt inhibitor
wnt inhibitors
present
Prior art date
Application number
JOJO/P/2017/0148A
Other languages
English (en)
Inventor
Leslie Harris Jennifer
Gergely Peter
Liu Jun
Svensson Eric
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20170148A1 publication Critical patent/JOP20170148A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمثبط Wnt بالصيغة (I) للاستخدام في علاج التليف و بعض اضطرابات التليف مثل متلازمة صلابة الجلد و التصلب الجهازي. يوفر الاختراع الحالي أيضاً طريقة لعلاج التليف، تركيبة صيدلانية تضم مثبط Wnt بالصيغة (I) و عنصر نشط ثاني للاستخدام في علاج التليف وأيضاً للاستخدام لمثبط Wnt بالصيغة (I) أو ملحه المقبول صيدلانياً لتصنيع دواء لعلاج التليف واضطرابات التليف.
JOJO/P/2017/0148A 2016-06-22 2017-06-21 مثبطات Wnt لعلاج التليف JOP20170148A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662353098P 2016-06-22 2016-06-22

Publications (1)

Publication Number Publication Date
JOP20170148A1 true JOP20170148A1 (ar) 2017-12-22

Family

ID=59276798

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2017/0148A JOP20170148A1 (ar) 2016-06-22 2017-06-21 مثبطات Wnt لعلاج التليف

Country Status (12)

Country Link
US (1) US20200306244A1 (ar)
EP (1) EP3475271A1 (ar)
JP (1) JP2019522658A (ar)
KR (1) KR20190019171A (ar)
CN (1) CN109415342A (ar)
AU (1) AU2017281980B2 (ar)
CA (1) CA3028586A1 (ar)
IL (1) IL263804A (ar)
JO (1) JOP20170148A1 (ar)
RU (1) RU2019101226A (ar)
TW (1) TW201803562A (ar)
WO (1) WO2017221142A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021128005A (ja) * 2020-02-12 2021-09-02 株式会社島津製作所 血液の前処理方法および検査方法
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112472701B (zh) * 2020-12-04 2021-08-31 复旦大学附属中山医院 Wnt抑制剂Wnt-C59在制备治疗SCN5A突变致扩张型心肌病的药物中的应用
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
WO2016191525A1 (en) * 2015-05-26 2016-12-01 Curegenix Corporation Tumor biomarkers and use thereof
US20180153884A1 (en) * 2015-05-31 2018-06-07 Curegenix Corporation Combination compositions for immunotherapy

Also Published As

Publication number Publication date
KR20190019171A (ko) 2019-02-26
CA3028586A1 (en) 2017-12-28
WO2017221142A1 (en) 2017-12-28
IL263804A (en) 2019-01-31
JP2019522658A (ja) 2019-08-15
RU2019101226A (ru) 2020-07-22
AU2017281980A1 (en) 2019-01-17
CN109415342A (zh) 2019-03-01
TW201803562A (zh) 2018-02-01
US20200306244A1 (en) 2020-10-01
EP3475271A1 (en) 2019-05-01
AU2017281980B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
CY1125488T1 (el) Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6
UA118149C2 (uk) Інгібітор jak
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2016109217A3 (en) Btk inhibitors
CR20210480A (es) Formulaciones farmacéuticas
GEAP202215599A (en) Boron containing pde4 inhibitors
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
EP4252856A3 (en) Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
MX2023001721A (es) Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин
JOP20190054B1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид